Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 2/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1785881 | 0.82 | ALDH1A1 (0.42) | ALDH1A1HPGDHTTSMN1; SMN2MEN1 | |
| SCHEMBL2843121 | 0.78 | ALDH1A1 (0.50) | ALDH1A1HPGDLMNATDP1L3MBTL1 | |
| SCHEMBL1806887 | 0.78 | TDP1 (0.47) | ALDH1A1MEN1LMNATHRBBLM | |
| SCHEMBL31306389 | 0.78 | TDP1 (0.47) | ALDH1A1MEN1LMNATHRBBLM | |
| SCHEMBL31306390 | 0.78 | TDP1 (0.47) | ALDH1A1MEN1LMNATHRBBLM | |
| SCHEMBL2544586 | 0.74 | LMNA (0.49) | ALDH1A1HPGDHTTSMN1; SMN2LMNA | |
| SCHEMBL1786709 | 0.74 | CYP2C9 (0.37) | — | |
| SCHEMBL10418797 | 0.73 | ALDH1A1 (0.34) | ALDH1A1TDP1L3MBTL1ERN1KCNJ1 | |
| SCHEMBL6242749 | 0.72 | ALDH1A1 (0.36) | ALDH1A1HPGDHTTSMN1; SMN2MEN1 | |
| SCHEMBL288166 | 0.72 | CES2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113613652-B | Benzimidazole compounds and their use in the treatment of alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2022-08-23 | — | — | CN | disclosed |
| CN-114014844-A | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-113613652-A | Benzimidazole compounds and their use for treating alzheimer's disease or huntington's disease | 台湾卫生研究院 | 2021-11-05 | — | — | CN | disclosed |
| CN-109641871-B | Aminopyridine derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112533598-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20210053926-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-25 | — | — | US | disclosed |
| US-10781184-B2 | Substituted benzazinones as antibacterial compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-09-22 | — | — | US | disclosed |
| US-20180362474-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-20 | — | — | US | disclosed |
| EP-3386950-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017098440-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8822518-B2 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | GLAXOSMITHKLINE LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC (US) | 2014-04-10 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION | 2010-09-02 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | ALDH1A1 3500/4885HPGD 1582/4885HTT 2138/4885 |
| US-20210053926-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | LPXN, MLX, ZYX | ALDH1A1 2221/4885HPGD 1568/4885HTT 4821/4885 |
| US-20180362474-A1 | SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS | LPXN, MLX, ZYX | ALDH1A1 2221/4885HPGD 1568/4885HTT 4821/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | ALDH1A1 4254/4885HPGD 1893/4885HTT 1729/4885 |
| US-10781184-B2 | Substituted benzazinones as antibacterial compounds | LPXN, MLX, ZYX | ALDH1A1 2221/4885HPGD 1568/4885HTT 4821/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | ALDH1A1 3500/4885HPGD 1582/4885HTT 2138/4885 |
| US-20100222345-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | ALDH1A1 3109/4885HPGD 1627/4885HTT 1472/4885 |
| US-20140100255-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | ALDH1A1 3500/4885HPGD 1582/4885HTT 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.